Development of a method for predicting prognosis after treatment of nasopharyngeal carcinoma using EB virus-related microRNA

2023 Fiscal Year Final Research Report

• Project/Area Number: 19K18725
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56050:Otorhinolaryngology-related
• Research Institution: Kanazawa University
• Principal Investigator: AOKI Yoshitaka 金沢大学, 医学系, 協力研究員 (00837172)
• Project Period (FY): 2019-04-01 – 2024-03-31
• Keywords: BART miRNA / EBV / 上咽頭癌

Outline of Final Research Achievements

There are 44 types of Bam HI A rightward transcript miRNA (BART miRNA), which is a miRNA produced by EBV-associated nasopharyngeal carcinoma cells. When BART miRNAs were quantified from serum of EBER-positive nasopharyngeal carcinoma patients, miR-BART17-5p was found to be the most abundant. It is necessary to continue to investigate the most useful marker for early detection of nasopharyngeal carcinoma by closely examining serum from cases and recurrences.

Free Research Field

耳鼻咽喉科頭頚部外科

Academic Significance and Societal Importance of the Research Achievements

上咽頭癌は初発診断時には70%の症例でリンパ節転移を来しており、また、解剖学的な理由により手術が困難なのが特徴であるため、今後上咽頭がんにおける血液採取などにより、がん細胞由来の物質を調査することで再発病変を早期にとらえることが可能になるための一助となる。